Figure 6.
TNB-486 induces tumor regression in multiple xenograft models of established tumors. (a) 1 × 106 Raji-luc cells were injected i.v via tail vein into CIEA-NOG mice (N = 5/group). On day 6 post-implantation (pi), 10 × 106 human PBMCs were injected i.v. TNB-486, NC or PC, at the respective doses shown, was injected on days 7, 14 and 21. GvHD/GvT onset was observed by day 15 pi and hence data points after day 14 are not shown. (b and c) CIEA-NOG mice (N = 10/group) received 10 × 106 SUDHL-10 cells (b) or Nalm-6 cells (c) with 50% Matrigel subcutaneously in the lower right flank. When tumor volume reached 200 mm3, mice received 10 × 106 human PBMCs i. v followed by antibody treatment Q4D as shown in the figure. Statistical analyses were performed by Two-way ANOVA on GraphPad Prism. TNB-486 treated animals were compared with PBMC + vehicle treated animals. A value of p < .05 was considered significant